{"Title": ["Infinity (INFI) Upgraded to Buy: Here's What You Should Know", "Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict", "Spectrum Pharma (SPPI) Withdraws Rolontis BLA, Shares Down", "Infinity Inks Deal With Roche for Phase II Study of IPI-549", "Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates", "Health Care Sector Update for 03/06/2019: VLRX, OPTN, INFI, JNJ, PFE, MRK, ABT, AMGN", "Health Care Sector Update for 03/06/2019: HZNP,INFI,HCR,VSTM,SRPT,LGND,NVS", "Health Care Sector Update for 03/06/2019: LGND,NVS,INFI,HCR,VSTM,SRPT", "Infinity (INFI) Upgraded to Buy: Here's What You Should Know", "Infinity (INFI) Down 48.3% Since Last Earnings Report: Can It Rebound?", "Monday Sector Laggards: Semiconductors, Biotechnology Stocks", "Mid-Day Market Update: Dow Down Over 400 Points; Apptio Shares Spike Higher", "Mid-Morning Market Update: Markets Open Lower; Veritas Capital To Buy Athenahealth For $5.7B", "Mid-Afternoon Market Update: OPKO Health Rises On Q3 Earnings; Lumentum Shares Plummet", "Bristol-Myers, Infinity to Test Opdivo Combo for Bladder Cancer", "Infinity (INFI) Q3 Earnings Beat Estimates, Revenues Up Y/Y", "Health Care Sector Update for 03/06/2019: LGND,NVS,INFI,HCR,VSTM,SRPT", "The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis", "Options Traders Expect Huge Moves in Infinity (INFI) Stock", "Infinity (INFI) Up 21.9% Since Last Earnings Report: Can It Continue?", "Infinity Focuses on Developing IPI-549 for Solid Tumors", "Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2", "Infinity and Arcus Ink Deal for Two Triple Combo Studies", "Health Care Sector Update for 06/26/2018: INFI,RCUS,XERS,SNSS,SENS", "Infinity Pharmaceuticals (INFI) Looks Good: Stock Adds 6.5% in Session", "The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis", "Options Traders Expect Huge Moves in Infinity (INFI) Stock", "Infinity (INFI) Up 21.9% Since Last Earnings Report: Can It Continue?", "Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y", "Medicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/Y", "AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains", "Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline", "Infinity Pharmaceuticals (INFI) Down 6.7% Since Earnings Report: Can It Rebound?", "Infinity (INFI) Incurs In-Line Loss in Q1, Maintains View", "Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates", "Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y", "Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y", "Medicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/Y", "AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains", "Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline", "Infinity Pharmaceuticals (INFI) Down 6.7% Since Earnings Report: Can It Rebound?", "Why Infinity Pharmaceuticals (INFI) Could Shock the Market Soon", "Karyopharm's Myeloma Candidate Gets Fast Track Designation", "FDA Prolongs Review Date for AbbVie Endometriosis Candidate", "Can The Uptrend Continue for Infinity Pharmaceuticals (INFI)?", "Infinity (INFI) Reports Narrower-than-Expected Loss in Q4", "Mid-Afternoon Market Update: Freshpet Slides On Earnings Miss; CommerceHub Shares Surge", "Infinity Provides Update on Lead Candidate, Issues 2018 View", "Why Is Infinity Pharmaceuticals (INFI) Down 18.3% Since its Last Earnings Report?", "Options Traders Expect Huge Moves in Infinity Pharmaceuticals (INFI) Stock", "Mid-Day Market Update: Omeros Climbs After Strong Q3 Results; LightPath Technologies Shares Plunge", "Mid-Morning Market Update: Markets Open Lower; J C Penney Sales Beat Estimates", "Pre-Market Most Active for Nov 10, 2017 : JCP, NVDA, ROKU, SOGO, TVIX, QQQ, SOI, TLT, INFI, ATTO, ITUB, SNAP", "Infinity (INFI) Q3 Loss Narrower than Expected, View Intact", "Mid-Day Market Update: Crude Oil Up Over 1%; Tandem Diabetes Care Shares Plunge", "Mid-Morning Market Update: Markets Open Higher; Bank of America Profit Beats Expectations", "Thursday 12/7 Insider Buying Report: INFI, CRK", "Mid-Day Market Update: J.Jill Tumbles Following Weak Q3 Outlook; Ardelyx Shares Surge", "Seattle Genetics Inks Clinical Collaborations for Cancer Drug", "Mid-Morning Market Update: Markets Edge Lower; JPMorgan Profit Beats Estimates", "Pre-Market Most Active for Oct 12, 2017 : MU, AZN, ACRX, ARDX, INFI, JILL, BAC, C, GSK, SNAP, MNKD, TVIX", "Health Care Sector Update for 10/12/2017: AMPE,INFI,ACRX", "Infinity (INFI) Reports Narrower-than-Expected Loss in Q1", "Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised", "Infinity Pharmaceuticals, Inc. (INFI) in Focus: Stock Moves 12% Higher", "Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal", "Infinity (INFI) Q2 Loss Wider than Expected, View Intact", "Infinity Pharmaceuticals (INFI) Down 5.3% Since Earnings Report: Can It Rebound?", "Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1", "Catalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1", "VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y", "Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates", "Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View", "Horizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed", "Endo (ENDP) Beats on Q1 Earnings, Reaffirms '17 Guidance", "Catalent (CTLT) Shows Strength: Stock Adds 9.8% in Session", "Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat", "Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1", "VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y", "Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates", "Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View", "Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y", "Shire (SHPG) Beats on Q1 Earnings & Sales, Reiterates View", "Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates", "Why Is Infinity (INFI) Down 37.4% Since the Last Earnings Report?", "AMAG Files for FDA Approval of Subcutaneous Form of Makena", "Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Earnings Miss Estimates", "Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19%", "Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View", "AbbVie (ABBV) Presents Positive Data on HCV Combination Drug", "Nivalis' (NVLS) Shares Down After Merger Deal with Alpine", "Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III", "Why Is Infinity (INFI) Down 37.4% Since the Last Earnings Report?", "AMAG Files for FDA Approval of Subcutaneous Form of Makena", "Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Earnings Miss Estimates", "Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19%", "Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View", "Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher", "Should You Retain Universal Health (UHS) Stock in Portfolio?", "Ultragenyx's (RARE) XLH Drug Positive in Phase II Study", "Here's Why You Should Dump Tenet Healthcare (THC) Stock Now", "Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549", "New Strong Buy Stocks for April 10th", "Cardiome Pharma (CRME) Jumps: Stock Adds 6.6% in Session", "Mid-Afternoon Market Update: GNC Gains On Upbeat Earnings; Barracuda Shares Drop", "Increased Earnings Estimates Seen for Infinity (INFI): Can It Move Higher?", "WellCare and Catholic Health Team Up to Improve Health Care", "Community Health Completes Tender Offer for Senior Notes", "What Makes Valeant Pharmaceuticals (VRX) a Strong Sell?", "Should You Get Rid of Patheon (PTHN) Now?", "What Makes Tesaro (TSRO) a Strong Sell?", "Are Options Traders Betting on a Big Move in Infinity Pharmaceuticals (INFI) Stock?", "Should You Retain Acadia Healthcare Stock in Your Portfolio?", "Infinity Pharma Focuses on Cancer Drug: Competition Looms", "Infinity (INFI) Reports Narrower-than-Expected Loss in Q4", "Mid-Morning Market Update: Markets Edge Lower; Abercrombie & Fitch Earnings Miss Views", "Infinity Pharmaceuticals (INFI) Catches Eye: Stock Up 13.5%", "Health Care Sector Update for 01/20/2017: INFI,IDXG,PSTI", "VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3", "Endocyte (ECYT) Stock Up on Lower-than-Expected Q3 Loss", "3 Reasons Why Infinity Pharmaceuticals (INFI) is a Great Momentum Stock", "VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3", "Keryx (KERX) Q3 Loss Wider than Expected, Restores Supply", "Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q3", "Mylan (MYL) Q3 Earnings & Revenues Miss on EpiPen Woes", "Mannkind (MNKD) Q3 Earnings Beat, Inks Deal with Sanofi", "ARIAD (ARIA) Stock Up on Narrower-than-Expected Q3 Loss", "Arena (ARNA) Q3 Loss Lower than Expected, Revenues Rise", "Conatus (CNAT) Reports Narrower-than-Expected Loss in Q3", "Ophthotech (OPHT) Q3 Loss Wider than Expected, Sales Fall", "Valeant Pharma (VRX) Q3 Earnings Miss, Slashes Guidance", "Celldex (CLDX) Q3 Loss Narrower than Expected, Sales Beat", "Repros (RPRX) Loss Narrower Y/Y in Q3, Pipeline in Focus", "Endo (ENDP) Q3 Earnings & Revenues Beat; View Intact", "ARIAD (ARIA) Stock Up on Narrower-than-Expected Q3 Loss", "Arena (ARNA) Q3 Loss Lower than Expected, Revenues Rise", "Conatus (CNAT) Reports Narrower-than-Expected Loss in Q3", "Horizon (HZNP) Stock Up Despite Q3 Earnings, Revenue Miss", "Immune Design (IMDZ) Worth a Look: Stock Up 5% in Session", "AVEO Pharmaceuticals' (AVEO) Q3 Loss Lower than Expected", "Intercept (ICPT) Q3 Loss Narrower than Expected, Sales Miss", "Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3", "Aduro (ADRO) Stock Down on Wider-than-Expected Q3 Loss", "Geron (GERN) Reports Narrower-than-Expected Loss in Q3", "Humana (HUM) Partners with MDLIVE, Improves MA Plans", "Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3", "Aerie (AERI) Q3 Loss Wider than Expected, Pipeline in Focus", "Momenta (MNTA) Q3 Loss Narrower than Expected, Sales Up", "Alkermes (ALKS) Q3 Loss in Line, Sales Miss; '16 View Intact", "Alnylam (ALNY) Q3 Loss Wider than Expected, Revenues Up", "Pacira (PCRX) Misses Q3 Earnings Estimates, Beats on Sales", "QLT's (QLTI) Reports In-Line Q3 Loss, Merger in Focus", "Radius Health (RDUS) Q3 Loss Match Estimates, Wider Y/Y", "Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3", "Aerie (AERI) Q3 Loss Wider than Expected, Pipeline in Focus", "Momenta (MNTA) Q3 Loss Narrower than Expected, Sales Up", "Alkermes (ALKS) Q3 Loss in Line, Sales Miss; '16 View Intact", "Alnylam (ALNY) Q3 Loss Wider than Expected, Revenues Up", "Pacira (PCRX) Misses Q3 Earnings Estimates, Beats on Sales", "QLT's (QLTI) Reports In-Line Q3 Loss, Merger in Focus", "Radius Health (RDUS) Q3 Loss Match Estimates, Wider Y/Y", "Shire (SHPG) Misses Q3 Earnings & Revenue Estimates", "AVEO Pharmaceuticals (AVEO) Q3 Earnings: What's in Store?", "Radius Health (RDUS): Will It Disappoint in Q3 Earnings?", "Horizon (HZNP) Q3 Earnings Preview: Stock to Disappoint?", "Epizyme (EPZM) Q3 Earnings: What's in Store for the Stock?", "Jazz Pharma (JAZZ) Q3 Earnings: A Disappointment in Store?", "Intercept (ICPT) Q3 Earnings Preview: What's in the Cards?", "Prothena (PRTA) Reports Wider-than-Expected Loss in Q3", "Geron (GERN) Q3 Earnings: Will the Store Pull a Surprise?", "Novo Nordisk (NVO) Tops Q3 Earnings, Revenues Up Y/Y", "ImmunoGen (IMGN) Reports Wider-than-Expected Loss", "ACADIA Pharma (ACAD): Will It Disappoint in Q3 Earnings?", "Exelixis (EXEL) Q3 Earnings: What's in Store for the Stock?", "Aerie Pharmaceuticals (AERI) Q3 Earnings: Will It Beat?", "Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q2", "ARIAD (ARIA): Is a Beat in the Cards this Earnings Season?", "United Therapeutics (UTHR) Beats Q3 Earnings, Sales Miss", "Agenus (AGEN) Reports Wider-than-Expected Loss in Q3", "McKesson (MCK) Misses on Q2 Earnings & Sales, Cuts View", "Seattle Genetics (SGEN) Loss Narrower than Expected in Q3", "AmerisourceBergen (ABC) Q3 Earnings: Will It Disappoint?", "Aerie Pharmaceuticals (AERI) Q3 Earnings: Will It Beat?", "Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q2", "What's Ahead for ImmunoGen (IMGN) This Earnings Season?", "Alkermes Depression Candidate Positive in Phase III Study", "McKesson (MCK) Q2 Earnings: Stock Likely to Disappoint?", "Alexion Graft-Versus-Host Disease Drug Wins Orphan Status", "Novartis (NVS) Q3 Earnings: Stock to Beat Estimates Again?", "Vertex (VRTX) Q3 Earnings: What's in Store for the Stock?", "3 Troubled Pharma Stocks That Could Rally Soon", "Inovio Stock Down on FDA Hold on VGX-3100 Phase III Study", "Infinity (INFI) at 52-Week Low on Disappointing Duvelisib Data", "Mid-Afternoon Market Update: Fed Leaves Rates Unchanged; Bob Evans Farms Shares Drop Following Weak Forecast", "Why Infinity Pharmaceuticals Inc. Is Being Obliterated Today", "Mid-Day Market Update: Yingli Green Energy Surges Following Q1 Earnings; Infinity Pharmaceuticals Shares Tumble", "Mid-Morning Market Update: Markets Mostly Lower; Isle of Capri Casinos Profit Beats Views", "Infinity Pharmaceuticals (INFI) Stock Tanks on Lymphoma Drug Letdown", "Mid-Afternoon Market Update: Crude Oil Down Over 1%; Motorcar Parts of America Shares Spike Higher", "Infinity Regains Duvelisib Rights, Announces Restructuring", "Quality Systems Beats Q3 Earnings, Lags Revenue Estimates", "Can Cardinal Health (CAH) Pull a Surprise in Q2 Earnings?", "Natus Medical (BABY) Beats on Q4 Earnings, Revenue in Line", "Varian (VAR) Beats Q1 Earnings and Revenue Estimates", "Varian (VAR) Q1 Earnings Preview: A Surprise in Store?", "The Zacks Analyst Blog Highlights: Aerie Pharmaceuticals, United Therapeutics, Pacira Pharmaceuticals, Ohr Pharmaceutical and Infinity Pharmaceuticals", "Intuitive Surgical (ISRG) Q4 Earnings: A Surprise in Store?", "ImmunoGen Posts Wider-than-Expected Loss, Retains View", "Can Infinity Pharmaceuticals (INFI) Keep the Earnings Streak Alive This Quarter?", "Mid-Afternoon Market Update: Crude Oil Slides Over 2%; MannKind Shares Dip On Termination Of Afrezza Deal With Sanofi", "Infinity (INFI) Completes Enrollment in Phase III DUO Study", "Infinity (INFI) Updates on Duvelisib and IPI-549 on R&D Day", "Health Care Sector Update for 10/06/2015: CPRX, INFI, FATE", "Infinity (INFI) Up, Set to Get Duvelisib Milestone Payment", "KemPharm (KMPH) Updates on Abuse-Deterrent Opioid Drug", "6 Drug Stocks That Look to Beat the Market in 2016", "Infinity Pharmaceuticals (INFI) Jumps: Stock Moves Up 8.6%", "Mylan (MYL) Launches Formal Offer to Acquire Perrigo", "Theravance/Mylan Advance COPD Candidate into Phase III", "Akebia (AKBA) Skyrockets on Encouraging Phase II Data", "Bristol-Myers and Pfizer Initiate Phase IV Study on Eliquis", "Mylan Set to Take Acquisition Offer to Perrigo Shareholders", "Exelixis' Cancer Drug Gets Breakthrough Therapy Status", "Epizyme (EPZM) Gains as Oncology Candidate Advances", "Vital Therapies Hit By Disappointing Data on Liver Drug", "Gilead's EU Regulatory Application for HIV Drug Validated", "Mylan Looking to Get Generic Version of Zytiga Approved", "AVEO Up on Novartis Collaboration for Cachexia Candidate", "Endo Gets Favorable Ruling Related to Opana ER in U.S.", "Bristol-Myers Leukemia Drug Sprycel's U.S. Label Updated", "Bristol-Myers' Cancer Drug Opdivo FDA Action Date Delayed", "Theravance Biopharma Posts Narrower Q2 Loss, View Revised - Analyst Blog", "AVEO Pharmaceuticals Posts Narrower-than-Expected Loss - Analyst Blog", "Infinity Pharmaceuticals' Stock Dipped 15% in July: Time to Buy?", "After Hours Most Active for Jun 2, 2015 : BBEP, QCOM, ACHN, OZM, NVAX, INFI, PDLI, TSM, HD, AA, GE, WRI", "Infinity Pharmaceuticals Exercises Duvelisib Royalty Option - Analyst Blog", "Why Infinity Pharmaceuticals (INFI) Could Be Positioned for a Surge? - Tale of the Tape", "Will Thoratec (THOR) Miss Earnings Estimates in Q4? - Analyst Blog", "Puma Biotechnology's (PBYI) Q2 Loss Wider than Expected", "Monday's ETF Movers: OIH, XBI", "Will AbbVie's $805 Million Agreement for Duvelisib Pay Off? - Analyst Blog", "Thursday's ETF with Unusual Volume: PBD", "Pre-Market Most Active for Sep 3, 2014 : VOYA, INFI, AAPL, QQQ, BAC, NOK, FB, TVIX, DAL, X, ALU, ACHN", "Infinity Pharma (INFI) Shares Skyrocket on Cancer Drug Partnership - Stocks in the News", "Why Infinity Pharmaceuticals Inc. Stock Skyrocketed", "NASDAQ Tumbles 0.5%; Infinity Pharmaceuticals Jumps On Deal With AbbVie", "Dividend Aristocrats: Time to Buy AbbVie Inc Stock?", "Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog", "Will AbbVie's $805 Million Agreement for Duvelisib Pay Off? - Analyst Blog", "Thursday's ETF with Unusual Volume: PBD", "Pre-Market Most Active for Sep 3, 2014 : VOYA, INFI, AAPL, QQQ, BAC, NOK, FB, TVIX, DAL, X, ALU, ACHN", "Infinity Pharmaceuticals (INFI) Jumps: Stock Adds 15.5% in Session - Tale of the Tape", "Positive Data on Infinity Pharma Candidate - Analyst Blog", "Markets Open Higher; Burger King In Talks To Buy Tim Hortons", "Commit To Buy Infinity Pharmaceuticals At $8, Earn 16.9% Using Options", "Infinity Pharma Down on Wider-than-Expected Loss - Analyst Blog", "Drugs That Disappointed Investors In 2013: Infinity's IPI-145", "Infinity Pharma bulls bet on bounce", "Infinity Pharma Widens Q2 Loss - Analyst Blog", "Infinity Pharmaceuticals Inc. (INFI) Enters Overbought Territory - Tale of the Tape", "Bulls hope Infinity lives up to name", "Mid-Day Market Update: Sysco Shares Rise Following Merger with US Foods; McDonald's Falls", "Mid-Morning Market Update: Markets Rise; Covidien To Buy Given Imaging For $30/Share", "Pre-Market Most Active for Dec 9, 2013 : GIVN, SYY, INFI, NOK, ALU, JCP, GILD, AAXJ, FB, BAC, CRNT, NJ", "Infinity Shares Up, Post Narrower Loss - Analyst Blog", "Mid-Day Market Update: Stocks Pare Gains, G-III Apparel Surges On Q1 Results", "Mid-Day Market Update: Markets Turn Mixed, Colonial Properties Gains On Acquisition News", "Mid-Morning Market Update: Markets Rise, Cracker Barrel Posts Upbeat Earnings", "Pre-Market Most Active for Jun 3, 2013 : BAC, QQQ, CLP, F, MRK, INTC, BCS, NBG, SIRI, AAPL, TSLA, INFI", "Positive Data on Infinity's Oncology Candidate - Analyst Blog", "Another vote of confidence in Infinity", "Mid-Afternoon Market Update: Optimer Falls as Halozyme Rockets Upwards", "Mid-Day Market Update: US Stocks Fluctuate, Cisco Systems Up on Better-than-Expected Earnings", "Insiders Buy Shares at AGCO and Texas Industries While Infinity Pharmaceuticals Sees a Major Sell-Off", "Pre-Market Most Active for Apr 11, 2013 : PCS, RAD, SGYP, INFI, MSFT, ACAD, RLGY, QQQ, FTNT, NOK, BAC, HPQ", "Infinity Reports Wider Loss - Analyst Blog", "Mid-Afternoon Market Update: Markets Recovering; Pandora Falls in Anticipation of Apple's Streaming Radio", "Infinity Pharma at 52-Week High - Analyst Blog", "ARIAD Announced Ponatinib Data - Analyst Blog", "Why one trader is selling Infinity calls", "Stocks Pointed Higher with Retail Sales, Fed in Focus", "Company News for January 30, 2012 - Corporate Summary", "Amgen, Celgene and Novartis in the Fight Against Pancreatic Cancer", "Infinity Provides Pipeline Update - Analyst Blog"], "Elapsed Time": ["MAR 25, 2019", "MAR 18, 2019", "MAR 18, 2019", "MAR 15, 2019", "MAR 14, 2019", "MAR 6, 2019", "MAR 6, 2019", "MAR 6, 2019", "MAR 25, 2019", "DEC 5, 2018", "NOV 12, 2018", "NOV 12, 2018", "NOV 12, 2018", "NOV 12, 2018", "NOV 7, 2018", "NOV 6, 2018", "MAR 6, 2019", "OCT 2, 2018", "SEP 26, 2018", "SEP 6, 2018", "AUG 22, 2018", "AUG 9, 2018", "JUN 27, 2018", "JUN 26, 2018", "OCT 3, 2018", "OCT 2, 2018", "SEP 26, 2018", "MAY 3, 2018", "APR 30, 2018", "APR 27, 2018", "APR 26, 2018", "APR 18, 2018", "JUN 7, 2018", "MAY 9, 2018", "MAY 3, 2018", "MAY 3, 2018", "APR 30, 2018", "APR 27, 2018", "APR 26, 2018", "APR 18, 2018", "JUN 7, 2018", "APR 12, 2018", "APR 11, 2018", "APR 11, 2018", "MAR 22, 2018", "MAR 16, 2018", "MAR 6, 2018", "JAN 26, 2018", "APR 16, 2018", "NOV 14, 2017", "NOV 10, 2017", "NOV 10, 2017", "NOV 10, 2017", "NOV 8, 2017", "OCT 13, 2017", "OCT 13, 2017", "DEC 7, 2017", "OCT 12, 2017", "OCT 12, 2017", "OCT 12, 2017", "OCT 12, 2017", "OCT 12, 2017", "MAY 10, 2017", "MAY 10, 2017", "OCT 9, 2017", "SEP 26, 2017", "AUG 4, 2017", "JUN 13, 2017", "MAY 11, 2017", "MAY 11, 2017", "MAY 4, 2017", "MAY 4, 2017", "MAY 10, 2017", "MAY 9, 2017", "MAY 9, 2017", "MAY 8, 2017", "MAY 5, 2017", "MAY 5, 2017", "MAY 4, 2017", "MAY 4, 2017", "MAY 10, 2017", "MAY 4, 2017", "MAY 3, 2017", "MAY 3, 2017", "APR 19, 2017", "APR 18, 2017", "APR 18, 2017", "APR 18, 2017", "APR 27, 2017", "APR 21, 2017", "APR 20, 2017", "APR 19, 2017", "APR 19, 2017", "APR 18, 2017", "APR 18, 2017", "APR 18, 2017", "APR 27, 2017", "APR 17, 2017", "APR 12, 2017", "APR 10, 2017", "APR 10, 2017", "APR 10, 2017", "APR 10, 2017", "APR 10, 2017", "APR 18, 2017", "APR 5, 2017", "APR 4, 2017", "MAR 31, 2017", "MAR 30, 2017", "MAR 29, 2017", "MAR 29, 2017", "MAR 28, 2017", "APR 5, 2017", "MAR 21, 2017", "MAR 15, 2017", "MAR 2, 2017", "MAR 1, 2017", "JAN 20, 2017", "NOV 12, 2016", "NOV 11, 2016", "MAR 23, 2017", "NOV 11, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 9, 2016", "NOV 8, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 8, 2016", "NOV 4, 2016", "NOV 3, 2016", "NOV 3, 2016", "NOV 3, 2016", "NOV 3, 2016", "NOV 3, 2016", "NOV 2, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 3, 2016", "NOV 3, 2016", "NOV 3, 2016", "NOV 3, 2016", "NOV 3, 2016", "NOV 2, 2016", "NOV 4, 2016", "NOV 2, 2016", "NOV 1, 2016", "NOV 1, 2016", "NOV 1, 2016", "NOV 1, 2016", "NOV 1, 2016", "NOV 1, 2016", "NOV 2, 2016", "NOV 1, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 26, 2016", "OCT 28, 2016", "OCT 28, 2016", "OCT 28, 2016", "OCT 28, 2016", "OCT 28, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 26, 2016", "OCT 24, 2016", "OCT 21, 2016", "OCT 21, 2016", "OCT 20, 2016", "OCT 20, 2016", "OCT 20, 2016", "AUG 8, 2016", "OCT 25, 2016", "JUN 15, 2016", "JUN 15, 2016", "JUN 14, 2016", "JUN 14, 2016", "JUN 14, 2016", "JUN 14, 2016", "JUN 14, 2016", "MAY 9, 2016", "JAN 29, 2016", "JAN 28, 2016", "JAN 28, 2016", "JAN 28, 2016", "JAN 25, 2016", "JAN 19, 2016", "JAN 18, 2016", "FEB 1, 2016", "JAN 15, 2016", "JAN 5, 2016", "NOV 18, 2015", "OCT 7, 2015", "OCT 6, 2015", "OCT 1, 2015", "SEP 25, 2015", "JAN 18, 2016", "SEP 22, 2015", "SEP 15, 2015", "SEP 15, 2015", "SEP 10, 2015", "SEP 10, 2015", "SEP 9, 2015", "AUG 25, 2015", "AUG 25, 2015", "AUG 24, 2015", "AUG 21, 2015", "AUG 19, 2015", "AUG 18, 2015", "AUG 17, 2015", "AUG 14, 2015", "AUG 13, 2015", "AUG 11, 2015", "AUG 11, 2015", "AUG 6, 2015", "JUN 2, 2015", "APR 1, 2015", "MAR 12, 2015", "FEB 6, 2015", "AUG 12, 2015", "DEC 15, 2014", "SEP 4, 2014", "SEP 4, 2014", "SEP 3, 2014", "SEP 3, 2014", "SEP 3, 2014", "SEP 3, 2014", "SEP 19, 2014", "SEP 10, 2014", "SEP 4, 2014", "SEP 4, 2014", "SEP 3, 2014", "FEB 26, 2014", "DEC 10, 2013", "AUG 25, 2014", "JUL 3, 2014", "MAY 8, 2014", "APR 28, 2014", "OCT 16, 2013", "AUG 15, 2013", "AUG 2, 2013", "JUL 19, 2013", "DEC 9, 2013", "DEC 9, 2013", "DEC 9, 2013", "NOV 12, 2013", "JUN 4, 2013", "JUN 3, 2013", "JUN 3, 2013", "JUN 3, 2013", "JUN 25, 2013", "JUN 18, 2013", "MAY 16, 2013", "MAY 16, 2013", "APR 17, 2013", "APR 11, 2013", "MAR 8, 2013", "JUN 3, 2013", "JAN 2, 2013", "DEC 17, 2012", "DEC 17, 2012", "MAR 13, 2012", "JAN 30, 2012", "OCT 26, 2010", "JAN 11, 2013"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/infinity-infi-upgraded-to-buy%3A-heres-what-you-should-know-2019-03-25", "https://www.nasdaq.com/articles/karyopharm-stock-up-even-as-fda-delays-selinexor-nda-verdict-2019-03-18", "https://www.nasdaq.com/articles/spectrum-pharma-sppi-withdraws-rolontis-bla-shares-down-2019-03-18", "https://www.nasdaq.com/articles/infinity-inks-deal-with-roche-for-phase-ii-study-of-ipi-549-2019-03-15", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-infi-reports-q4-loss-tops-revenue-estimates-2019-03-14", "https://www.nasdaq.com/articles/health-care-sector-update-03062019-vlrx-optn-infi-jnj-pfe-mrk-abt-amgn-2019-03-06", "https://www.nasdaq.com/articles/health-care-sector-update-03062019-hznpinfihcrvstmsrptlgndnvs-2019-03-06", "https://www.nasdaq.com/articles/health-care-sector-update-03062019-lgndnvsinfihcrvstmsrpt-2019-03-06", "https://www.nasdaq.com/articles/infinity-infi-upgraded-to-buy%3A-heres-what-you-should-know-2019-03-25", "https://www.nasdaq.com/articles/infinity-infi-down-48.3-since-last-earnings-report%3A-can-it-rebound-2018-12-05", "https://www.nasdaq.com/articles/monday-sector-laggards-semiconductors-biotechnology-stocks-2018-11-12", "https://www.nasdaq.com/articles/mid-day-market-update-dow-down-over-400-points-apptio-shares-spike-higher-2018-11-12", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-veritas-capital-buy-athenahealth-57b-2018-11", "https://www.nasdaq.com/articles/mid-afternoon-market-update-opko-health-rises-q3-earnings-lumentum-shares-plummet-2018-11", "https://www.nasdaq.com/articles/bristol-myers-infinity-to-test-opdivo-combo-for-bladder-cancer-2018-11-07", "https://www.nasdaq.com/articles/infinity-infi-q3-earnings-beat-estimates-revenues-up-y-y-2018-11-06", "https://www.nasdaq.com/articles/health-care-sector-update-03062019-lgndnvsinfihcrvstmsrpt-2019-03-06-0", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-champions-oncology-cytodyn-infinity-pharmaceuticals", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-infinity-infi-stock-2018-09-26", "https://www.nasdaq.com/articles/infinity-infi-up-21.9-since-last-earnings-report%3A-can-it-continue-2018-09-06", "https://www.nasdaq.com/articles/infinity-focuses-on-developing-ipi-549-for-solid-tumors-2018-08-22", "https://www.nasdaq.com/articles/infinity-infi-posts-narrower-than-expected-loss-in-q2-2018-08-09", "https://www.nasdaq.com/articles/infinity-and-arcus-ink-deal-for-two-triple-combo-studies-2018-06-27", "https://www.nasdaq.com/articles/health-care-sector-update-06262018-infircusxerssnsssens-2018-06-26", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-infi-looks-good%3A-stock-adds-6.5-in-session-2018-10-03", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-champions-oncology-cytodyn-infinity-pharmaceuticals", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-infinity-infi-stock-2018-09-26", "https://www.nasdaq.com/articles/acorda-acor-q1-earnings-miss-estimates-sales-down-y-y-2018-05-03", "https://www.nasdaq.com/articles/allergan-agn-q1-earnings-beat-estimates-sales-up-y-y-2018-04-30", "https://www.nasdaq.com/articles/medicines-companys-mdco-q1-loss-widens-revenues-tank-y-y-2018-04-27", "https://www.nasdaq.com/articles/abbvie-abbv-q1-earnings-beat-2018-view-up-stock-gains-2018-04-26", "https://www.nasdaq.com/articles/agios-leukemia-drug-bodes-well-for-growth-strong-pipeline-2018-04-18", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-infi-down-6.7-since-earnings-report%3A-can-it-rebound-2018-06-07", "https://www.nasdaq.com/articles/infinity-infi-incurs-in-line-loss-in-q1-maintains-view-2018-05-09", "https://www.nasdaq.com/articles/conatus-cnat-q1-loss-in-line-revenues-beat-estimates-2018-05-03", "https://www.nasdaq.com/articles/acorda-acor-q1-earnings-miss-estimates-sales-down-y-y-2018-05-03", "https://www.nasdaq.com/articles/allergan-agn-q1-earnings-beat-estimates-sales-up-y-y-2018-04-30", "https://www.nasdaq.com/articles/medicines-companys-mdco-q1-loss-widens-revenues-tank-y-y-2018-04-27", "https://www.nasdaq.com/articles/abbvie-abbv-q1-earnings-beat-2018-view-up-stock-gains-2018-04-26", "https://www.nasdaq.com/articles/agios-leukemia-drug-bodes-well-for-growth-strong-pipeline-2018-04-18", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-infi-down-6.7-since-earnings-report%3A-can-it-rebound-2018-06-07", "https://www.nasdaq.com/articles/why-infinity-pharmaceuticals-infi-could-shock-the-market-soon-2018-04-12", "https://www.nasdaq.com/articles/karyopharms-myeloma-candidate-gets-fast-track-designation-2018-04-11", "https://www.nasdaq.com/articles/fda-prolongs-review-date-for-abbvie-endometriosis-candidate-2018-04-11", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-infinity-pharmaceuticals-infi-2018-03-22", "https://www.nasdaq.com/articles/infinity-infi-reports-narrower-than-expected-loss-in-q4-2018-03-16", "https://www.nasdaq.com/articles/mid-afternoon-market-update-freshpet-slides-earnings-miss-commercehub-shares-surge-2018-03", "https://www.nasdaq.com/articles/infinity-provides-update-on-lead-candidate-issues-2018-view-2018-01-26", "https://www.nasdaq.com/articles/why-is-infinity-pharmaceuticals-infi-down-18.3-since-its-last-earnings-report-2018-04-16", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-infinity-pharmaceuticals-infi-stock-2017-11-14", "https://www.nasdaq.com/articles/mid-day-market-update-omeros-climbs-after-strong-q3-results-lightpath-technologies-shares", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-j-c-penney-sales-beat-estimates-2017-11-10", "https://www.nasdaq.com/articles/pre-market-most-active-nov-10-2017-jcp-nvda-roku-sogo-tvix-qqq-soi-tlt-infi-atto-itub-snap", "https://www.nasdaq.com/articles/infinity-infi-q3-loss-narrower-than-expected-view-intact-2017-11-08", "https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-over-1-tandem-diabetes-care-shares-plunge-2017-10-13", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-bank-america-profit-beats-expectations-2017", "https://www.nasdaq.com/articles/thursday-127-insider-buying-report-infi-crk-2017-12-07", "https://www.nasdaq.com/articles/mid-day-market-update-jjill-tumbles-following-weak-q3-outlook-ardelyx-shares-surge-2017-10", "https://www.nasdaq.com/articles/seattle-genetics-inks-clinical-collaborations-for-cancer-drug-2017-10-12", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-lower-jpmorgan-profit-beats-estimates-2017-10-12", "https://www.nasdaq.com/articles/pre-market-most-active-oct-12-2017-mu-azn-acrx-ardx-infi-jill-bac-c-gsk-snap-mnkd-tvix", "https://www.nasdaq.com/articles/catalyst-pharmaceuticals-cprx-posts-loss-as-expected-in-q1-2017-05-11", "https://www.nasdaq.com/articles/infinity-infi-reports-narrower-than-expected-loss-in-q1-2017-05-10", "https://www.nasdaq.com/articles/valeant-vrx-q1-earnings-revenues-miss-view-raised-2017-05-10", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-inc.-infi-in-focus%3A-stock-moves-12-higher-2017-10-09", "https://www.nasdaq.com/articles/infinity-bristol-myers-adds-tnbc-patients-to-clinical-deal-2017-09-26", "https://www.nasdaq.com/articles/infinity-infi-q2-loss-wider-than-expected-view-intact-2017-08-04", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-infi-down-5.3-since-earnings-report%3A-can-it-rebound-2017-06-13", "https://www.nasdaq.com/articles/endocyte-ecyt-reports-narrower-than-expected-loss-in-q1-2017-05-11", "https://www.nasdaq.com/articles/catalyst-pharmaceuticals-cprx-posts-loss-as-expected-in-q1-2017-05-11", "https://www.nasdaq.com/articles/vivus-vvus-loss-narrower-than-expected-revenues-up-y-y-2017-05-04", "https://www.nasdaq.com/articles/regeneron-regn-q1-earnings-miss-revenues-beat-estimates-2017-05-04", "https://www.nasdaq.com/articles/prothena-prta-q1-loss-narrower-than-expected-updates-view-2017-05-10", "https://www.nasdaq.com/articles/horizon-hznp-falls-on-q1-earnings-miss-guidance-trimmed-2017-05-09", "https://www.nasdaq.com/articles/endo-endp-beats-on-q1-earnings-reaffirms-17-guidance-2017-05-09", "https://www.nasdaq.com/articles/catalent-ctlt-shows-strength%3A-stock-adds-9.8-in-session-2017-05-08", "https://www.nasdaq.com/articles/intercept-icpt-q1-loss-narrower-than-expected-sales-beat-2017-05-05", "https://www.nasdaq.com/articles/agenus-agen-reports-narrower-than-expected-loss-in-q1-2017-05-05", "https://www.nasdaq.com/articles/vivus-vvus-loss-narrower-than-expected-revenues-up-y-y-2017-05-04", "https://www.nasdaq.com/articles/regeneron-regn-q1-earnings-miss-revenues-beat-estimates-2017-05-04", "https://www.nasdaq.com/articles/prothena-prta-q1-loss-narrower-than-expected-updates-view-2017-05-10", "https://www.nasdaq.com/articles/novo-nordisk-nvo-beats-on-q1-earnings-revenues-down-y-y-2017-05-04", "https://www.nasdaq.com/articles/shire-shpg-beats-on-q1-earnings-sales-reiterates-view-2017-05-03", "https://www.nasdaq.com/articles/ultragenyxs-hypophosphatemia-drug-succeeds-in-phase-iii-2017-04-19", "https://www.nasdaq.com/articles/why-is-infinity-infi-down-37.4-since-the-last-earnings-report-2017-04-19", "https://www.nasdaq.com/articles/amag-files-for-fda-approval-of-subcutaneous-form-of-makena-2017-04-18", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-goldman-sachs-earnings-miss-estimates-2017-04", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-infi-looks-good%3A-stock-jumps-19-2017-04-18", "https://www.nasdaq.com/articles/alexion-alxn-tops-q1-earnings-revenues-ups-17-view-2017-04-27", "https://www.nasdaq.com/articles/abbvie-abbv-presents-positive-data-on-hcv-combination-drug-2017-04-21", "https://www.nasdaq.com/articles/nivalis-nvls-shares-down-after-merger-deal-with-alpine-2017-04-20", "https://www.nasdaq.com/articles/ultragenyxs-hypophosphatemia-drug-succeeds-in-phase-iii-2017-04-19", "https://www.nasdaq.com/articles/why-is-infinity-infi-down-37.4-since-the-last-earnings-report-2017-04-19", "https://www.nasdaq.com/articles/amag-files-for-fda-approval-of-subcutaneous-form-of-makena-2017-04-18", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-goldman-sachs-earnings-miss-estimates-2017-04", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-infi-looks-good%3A-stock-jumps-19-2017-04-18", "https://www.nasdaq.com/articles/alexion-alxn-tops-q1-earnings-revenues-ups-17-view-2017-04-27", "https://www.nasdaq.com/articles/bio-path-holdings-bpth-looks-good%3A-stock-moves-13-higher-2017-04-17", "https://www.nasdaq.com/articles/should-you-retain-universal-health-uhs-stock-in-portfolio-2017-04-12", "https://www.nasdaq.com/articles/ultragenyxs-rare-xlh-drug-positive-in-phase-ii-study-2017-04-10", "https://www.nasdaq.com/articles/heres-why-you-should-dump-tenet-healthcare-thc-stock-now-2017-04-10", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-focuses-on-lead-candidate-ipi-549-2017-04-10", "https://www.nasdaq.com/articles/new-strong-buy-stocks-april-10th-2017-04-10", "https://www.nasdaq.com/articles/cardiome-pharma-crme-jumps%3A-stock-adds-6.6-in-session-2017-04-10", "https://www.nasdaq.com/articles/mid-afternoon-market-update-gnc-gains-upbeat-earnings-barracuda-shares-drop-2017-04-18", "https://www.nasdaq.com/articles/increased-earnings-estimates-seen-for-infinity-infi%3A-can-it-move-higher-2017-04-05", "https://www.nasdaq.com/articles/wellcare-and-catholic-health-team-up-to-improve-health-care-2017-04-04", "https://www.nasdaq.com/articles/community-health-completes-tender-offer-for-senior-notes-2017-03-31", "https://www.nasdaq.com/articles/what-makes-valeant-pharmaceuticals-vrx-a-strong-sell-2017-03-30", "https://www.nasdaq.com/articles/should-you-get-rid-of-patheon-pthn-now-2017-03-29", "https://www.nasdaq.com/articles/what-makes-tesaro-tsro-a-strong-sell-2017-03-29", "https://www.nasdaq.com/articles/are-options-traders-betting-on-a-big-move-in-infinity-pharmaceuticals-infi-stock-2017-03", "https://www.nasdaq.com/articles/should-you-retain-acadia-healthcare-stock-in-your-portfolio-2017-04-05", "https://www.nasdaq.com/articles/infinity-pharma-focuses-on-cancer-drug%3A-competition-looms-2017-03-21", "https://www.nasdaq.com/articles/infinity-infi-reports-narrower-than-expected-loss-in-q4-2017-03-15", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-lower-abercrombie-fitch-earnings-miss-views-2017-03", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-infi-catches-eye%3A-stock-up-13.5-2017-03-01", "https://www.nasdaq.com/articles/health-care-sector-update-01202017-infiidxgpsti-2017-01-20", "https://www.nasdaq.com/articles/vivus-vvus-reports-narrower-than-expected-loss-in-q3-2016-11-12", "https://www.nasdaq.com/articles/endocyte-ecyt-stock-up-on-lower-than-expected-q3-loss-2016-11-11", "https://www.nasdaq.com/articles/3-reasons-why-infinity-pharmaceuticals-infi-is-a-great-momentum-stock-2017-03-23", "https://www.nasdaq.com/articles/vivus-vvus-reports-narrower-than-expected-loss-in-q3-2016-11-11", "https://www.nasdaq.com/articles/keryx-kerx-q3-loss-wider-than-expected-restores-supply-2016-11-10", "https://www.nasdaq.com/articles/catalyst-cprx-reports-narrower-than-expected-loss-in-q3-2016-11-10", "https://www.nasdaq.com/articles/mylan-myl-q3-earnings-revenues-miss-on-epipen-woes-2016-11-10", "https://www.nasdaq.com/articles/endo-endp-q3-earnings-revenues-beat-view-intact-2016-11-08", "https://www.nasdaq.com/articles/ariad-aria-stock-up-on-narrower-than-expected-q3-loss-2016-11-08", "https://www.nasdaq.com/articles/arena-arna-q3-loss-lower-than-expected-revenues-rise-2016-11-08", "https://www.nasdaq.com/articles/conatus-cnat-reports-narrower-than-expected-loss-in-q3-2016-11-09", "https://www.nasdaq.com/articles/ophthotech-opht-q3-loss-wider-than-expected-sales-fall-2016-11-09", "https://www.nasdaq.com/articles/valeant-pharma-vrx-q3-earnings-miss-slashes-guidance-2016-11-09", "https://www.nasdaq.com/articles/celldex-cldx-q3-loss-narrower-than-expected-sales-beat-2016-11-09", "https://www.nasdaq.com/articles/repros-rprx-loss-narrower-y-y-in-q3-pipeline-in-focus-2016-11-09", "https://www.nasdaq.com/articles/endo-endp-q3-earnings-revenues-beat-view-intact-2016-11-08", "https://www.nasdaq.com/articles/ariad-aria-stock-up-on-narrower-than-expected-q3-loss-2016-11-08", "https://www.nasdaq.com/articles/arena-arna-q3-loss-lower-than-expected-revenues-rise-2016-11-08", "https://www.nasdaq.com/articles/conatus-cnat-reports-narrower-than-expected-loss-in-q3-2016-11-09", "https://www.nasdaq.com/articles/horizon-hznp-stock-up-despite-q3-earnings-revenue-miss-2016-11-08", "https://www.nasdaq.com/articles/immune-design-imdz-worth-a-look%3A-stock-up-5-in-session-2016-11-07", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-q3-loss-lower-than-expected-2016-11-07", "https://www.nasdaq.com/articles/intercept-icpt-q3-loss-narrower-than-expected-sales-miss-2016-11-04", "https://www.nasdaq.com/articles/aegerion-aegr-reports-narrower-than-expected-loss-in-q3-2016-11-04", "https://www.nasdaq.com/articles/aduro-adro-stock-down-on-wider-than-expected-q3-loss-2016-11-04", "https://www.nasdaq.com/articles/geron-gern-reports-narrower-than-expected-loss-in-q3-2016-11-04", "https://www.nasdaq.com/articles/humana-hum-partners-with-mdlive-improves-ma-plans-2016-11-08", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-loss-in-q3-2016-11-04", "https://www.nasdaq.com/articles/aerie-aeri-q3-loss-wider-than-expected-pipeline-in-focus-2016-11-03", "https://www.nasdaq.com/articles/momenta-mnta-q3-loss-narrower-than-expected-sales-up-2016-11-03", "https://www.nasdaq.com/articles/alkermes-alks-q3-loss-in-line-sales-miss-16-view-intact-2016-11-03", "https://www.nasdaq.com/articles/alnylam-alny-q3-loss-wider-than-expected-revenues-up-2016-11-03", "https://www.nasdaq.com/articles/pacira-pcrx-misses-q3-earnings-estimates-beats-on-sales-2016-11-03", "https://www.nasdaq.com/articles/qlts-qlti-reports-in-line-q3-loss-merger-in-focus-2016-11-02", "https://www.nasdaq.com/articles/radius-health-rdus-q3-loss-match-estimates-wider-y-y-2016-11-04", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-loss-in-q3-2016-11-04", "https://www.nasdaq.com/articles/aerie-aeri-q3-loss-wider-than-expected-pipeline-in-focus-2016-11-03", "https://www.nasdaq.com/articles/momenta-mnta-q3-loss-narrower-than-expected-sales-up-2016-11-03", "https://www.nasdaq.com/articles/alkermes-alks-q3-loss-in-line-sales-miss-16-view-intact-2016-11-03", "https://www.nasdaq.com/articles/alnylam-alny-q3-loss-wider-than-expected-revenues-up-2016-11-03", "https://www.nasdaq.com/articles/pacira-pcrx-misses-q3-earnings-estimates-beats-on-sales-2016-11-03", "https://www.nasdaq.com/articles/qlts-qlti-reports-in-line-q3-loss-merger-in-focus-2016-11-02", "https://www.nasdaq.com/articles/radius-health-rdus-q3-loss-match-estimates-wider-y-y-2016-11-04", "https://www.nasdaq.com/articles/shire-shpg-misses-q3-earnings-revenue-estimates-2016-11-02", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-q3-earnings%3A-whats-in-store-2016-11-01", "https://www.nasdaq.com/articles/radius-health-rdus%3A-will-it-disappoint-in-q3-earnings-2016-11-01", "https://www.nasdaq.com/articles/horizon-hznp-q3-earnings-preview%3A-stock-to-disappoint-2016-11-01", "https://www.nasdaq.com/articles/epizyme-epzm-q3-earnings%3A-whats-in-store-for-the-stock-2016-11-01", "https://www.nasdaq.com/articles/jazz-pharma-jazz-q3-earnings%3A-a-disappointment-in-store-2016-11-01", "https://www.nasdaq.com/articles/intercept-icpt-q3-earnings-preview%3A-whats-in-the-cards-2016-11-01", "https://www.nasdaq.com/articles/prothena-prta-reports-wider-than-expected-loss-in-q3-2016-11-02", "https://www.nasdaq.com/articles/geron-gern-q3-earnings%3A-will-the-store-pull-a-surprise-2016-11-01", "https://www.nasdaq.com/articles/novo-nordisk-nvo-tops-q3-earnings-revenues-up-y-y-2016-10-31", "https://www.nasdaq.com/articles/immunogen-imgn-reports-wider-than-expected-loss-2016-10-31", "https://www.nasdaq.com/articles/acadia-pharma-acad%3A-will-it-disappoint-in-q3-earnings-2016-10-31", "https://www.nasdaq.com/articles/amerisourcebergen-abc-q3-earnings%3A-will-it-disappoint-2016-10-27", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-aeri-q3-earnings%3A-will-it-beat-2016-10-27", "https://www.nasdaq.com/articles/dr.-reddys-rdy-earnings-revenues-decline-y-y-in-q2-2016-10-26", "https://www.nasdaq.com/articles/ariad-aria%3A-is-a-beat-in-the-cards-this-earnings-season-2016-10-28", "https://www.nasdaq.com/articles/united-therapeutics-uthr-beats-q3-earnings-sales-miss-2016-10-28", "https://www.nasdaq.com/articles/agenus-agen-reports-wider-than-expected-loss-in-q3-2016-10-28", "https://www.nasdaq.com/articles/mckesson-mck-misses-on-q2-earnings-sales-cuts-view-2016-10-28", "https://www.nasdaq.com/articles/seattle-genetics-sgen-loss-narrower-than-expected-in-q3-2016-10-28", "https://www.nasdaq.com/articles/amerisourcebergen-abc-q3-earnings%3A-will-it-disappoint-2016-10-27", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-aeri-q3-earnings%3A-will-it-beat-2016-10-27", "https://www.nasdaq.com/articles/dr.-reddys-rdy-earnings-revenues-decline-y-y-in-q2-2016-10-26", "https://www.nasdaq.com/articles/whats-ahead-for-immunogen-imgn-this-earnings-season-2016-10-24", "https://www.nasdaq.com/articles/alkermes-depression-candidate-positive-in-phase-iii-study-2016-10-21", "https://www.nasdaq.com/articles/mckesson-mck-q2-earnings%3A-stock-likely-to-disappoint-2016-10-21", "https://www.nasdaq.com/articles/alexion-graft-versus-host-disease-drug-wins-orphan-status-2016-10-20", "https://www.nasdaq.com/articles/novartis-nvs-q3-earnings%3A-stock-to-beat-estimates-again-2016-10-20", "https://www.nasdaq.com/articles/vertex-vrtx-q3-earnings%3A-whats-in-store-for-the-stock-2016-10-20", "https://www.nasdaq.com/articles/3-troubled-pharma-stocks-that-could-rally-soon-2016-08-08", "https://www.nasdaq.com/articles/inovio-stock-down-on-fda-hold-on-vgx-3100-phase-iii-study-2016-10-25", "https://www.nasdaq.com/articles/infinity-infi-at-52-week-low-on-disappointing-duvelisib-data-2016-06-15", "https://www.nasdaq.com/articles/mid-afternoon-market-update-fed-leaves-rates-unchanged-bob-evans-farms-shares-drop", "https://www.nasdaq.com/articles/why-infinity-pharmaceuticals-inc-being-obliterated-today-2016-06-14", "https://www.nasdaq.com/articles/mid-day-market-update-yingli-green-energy-surges-following-q1-earnings-infinity", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mostly-lower-isle-capri-casinos-profit-beats-views-2016", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-infi-stock-tanks-lymphoma-drug-letdown-2016-06-14", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-down-over-1-motorcar-parts-america-shares-spike", "https://www.nasdaq.com/articles/mid-day-market-update-tetra-technologies-drops-following-weak-results-krispy-kreme-shares", "https://www.nasdaq.com/articles/quality-systems-beats-q3-earnings-lags-revenue-estimates-2016-01-29", "https://www.nasdaq.com/articles/can-cardinal-health-cah-pull-a-surprise-in-q2-earnings-2016-01-28", "https://www.nasdaq.com/articles/natus-medical-baby-beats-on-q4-earnings-revenue-in-line-2016-01-28", "https://www.nasdaq.com/articles/varian-var-beats-q1-earnings-and-revenue-estimates-2016-01-28", "https://www.nasdaq.com/articles/varian-var-q1-earnings-preview%3A-a-surprise-in-store-2016-01-25", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-aerie-pharmaceuticals-united-therapeutics-pacira", "https://www.nasdaq.com/articles/intuitive-surgical-isrg-q4-earnings%3A-a-surprise-in-store-2016-01-18", "https://www.nasdaq.com/articles/immunogen-posts-wider-than-expected-loss-retains-view-2016-02-01", "https://www.nasdaq.com/articles/can-infinity-pharmaceuticals-infi-keep-the-earnings-streak-alive-this-quarter-2016-01-15", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-slides-over-2-mannkind-shares-dip-termination", "https://www.nasdaq.com/articles/infinity-infi-completes-enrollment-in-phase-iii-duo-study-2015-11-18", "https://www.nasdaq.com/articles/infinity-infi-updates-on-duvelisib-and-ipi-549-on-rd-day-2015-10-07", "https://www.nasdaq.com/articles/health-care-sector-update-10062015-cprx-infi-fate-2015-10-06", "https://www.nasdaq.com/articles/infinity-infi-up-set-to-get-duvelisib-milestone-payment-2015-10-01", "https://www.nasdaq.com/articles/kempharm-kmph-updates-on-abuse-deterrent-opioid-drug-2015-09-25", "https://www.nasdaq.com/articles/6-drug-stocks-that-look-to-beat-the-market-in-2016-2016-01-18", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-infi-jumps%3A-stock-moves-up-8.6-2015-09-22", "https://www.nasdaq.com/articles/mylan-myl-launches-formal-offer-to-acquire-perrigo-2015-09-15", "https://www.nasdaq.com/articles/theravance-mylan-advance-copd-candidate-into-phase-iii-2015-09-15", "https://www.nasdaq.com/articles/akebia-akba-skyrockets-on-encouraging-phase-ii-data-2015-09-10", "https://www.nasdaq.com/articles/bristol-myers-and-pfizer-initiate-phase-iv-study-on-eliquis-2015-09-10", "https://www.nasdaq.com/articles/mylan-set-to-take-acquisition-offer-to-perrigo-shareholders-2015-09-09", "https://www.nasdaq.com/articles/bristol-myers-cancer-drug-opdivo-fda-action-date-delayed-2015-08-13", "https://www.nasdaq.com/articles/epizyme-epzm-gains-as-oncology-candidate-advances-2015-08-25", "https://www.nasdaq.com/articles/vital-therapies-hit-by-disappointing-data-on-liver-drug-2015-08-24", "https://www.nasdaq.com/articles/gileads-eu-regulatory-application-for-hiv-drug-validated-2015-08-21", "https://www.nasdaq.com/articles/mylan-looking-to-get-generic-version-of-zytiga-approved-2015-08-19", "https://www.nasdaq.com/articles/aveo-up-on-novartis-collaboration-for-cachexia-candidate-2015-08-18", "https://www.nasdaq.com/articles/endo-gets-favorable-ruling-related-to-opana-er-in-u.s.-2015-08-17", "https://www.nasdaq.com/articles/bristol-myers-leukemia-drug-sprycels-u.s.-label-updated-2015-08-14", "https://www.nasdaq.com/articles/bristol-myers-cancer-drug-opdivo-fda-action-date-delayed-2015-08-13", "https://www.nasdaq.com/articles/theravance-biopharma-posts-narrower-q2-loss-view-revised-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-posts-narrower-than-expected-loss-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-stock-dipped-15-july-time-buy-2015-08-06", "https://www.nasdaq.com/articles/after-hours-most-active-jun-2-2015-bbep-qcom-achn-ozm-nvax-infi-pdli-tsm-hd-aa-ge-wri-2015", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-exercises-duvelisib-royalty-option-analyst-blog-2015-04-01", "https://www.nasdaq.com/articles/why-infinity-pharmaceuticals-infi-could-be-positioned-for-a-surge-tale-of-the-tape-2015-03", "https://www.nasdaq.com/articles/will-thoratec-thor-miss-earnings-estimates-in-q4-analyst-blog-2015-02-06", "https://www.nasdaq.com/articles/puma-biotechnologys-pbyi-q2-loss-wider-than-expected-2015-08-12", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-ties-infinity-keryx-slips-fda-approval-analyst-blog-2014-09", "https://www.nasdaq.com/articles/will-abbvies-%24805-million-agreement-for-duvelisib-pay-off-analyst-blog-2014-09-04", "https://www.nasdaq.com/articles/thursdays-etf-unusual-volume-pbd-2014-09-04", "https://www.nasdaq.com/articles/pre-market-most-active-sep-3-2014-voya-infi-aapl-qqq-bac-nok-fb-tvix-dal-x-alu-achn-2014", "https://www.nasdaq.com/articles/infinity-pharma-infi-shares-skyrocket-cancer-drug-partnership-stocks-news-2014-09-03", "https://www.nasdaq.com/articles/why-infinity-pharmaceuticals-inc-stock-skyrocketed-2014-09-03", "https://www.nasdaq.com/articles/nasdaq-tumbles-05-infinity-pharmaceuticals-jumps-deal-abbvie-2014-09-03", "https://www.nasdaq.com/articles/dividend-aristocrats-time-buy-abbvie-inc-stock-2014-09-19", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-ties-infinity-keryx-slips-fda-approval-analyst-blog-2014-09", "https://www.nasdaq.com/articles/will-abbvies-%24805-million-agreement-for-duvelisib-pay-off-analyst-blog-2014-09-04", "https://www.nasdaq.com/articles/thursdays-etf-unusual-volume-pbd-2014-09-04", "https://www.nasdaq.com/articles/pre-market-most-active-sep-3-2014-voya-infi-aapl-qqq-bac-nok-fb-tvix-dal-x-alu-achn-2014", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-infi-jumps%3A-stock-adds-15.5-in-session-tale-of-the-tape-2014-02", "https://www.nasdaq.com/articles/positive-data-on-infinity-pharma-candidate-analyst-blog-2013-12-10", "https://www.nasdaq.com/articles/markets-open-higher-burger-king-talks-buy-tim-hortons-2014-08-25", "https://www.nasdaq.com/articles/commit-buy-infinity-pharmaceuticals-8-earn-169-using-options-2014-07-03", "https://www.nasdaq.com/articles/infinity-pharma-down-on-wider-than-expected-loss-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/infinity-shares-up-post-narrower-loss-analyst-blog-2013-11-12", "https://www.nasdaq.com/articles/infinity-pharma-bulls-bet-bounce-2013-10-16", "https://www.nasdaq.com/articles/infinity-pharma-widens-q2-loss-analyst-blog-2013-08-15", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-inc.-infi-enters-overbought-territory-tale-of-the-tape-2013-08-02", "https://www.nasdaq.com/articles/bulls-hope-infinity-lives-name-2013-07-19", "https://www.nasdaq.com/articles/mid-day-market-update-sysco-shares-rise-following-merger-us-foods-mcdonalds-falls-2013-12", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-rise-covidien-buy-given-imaging-30share-2013-12-09", "https://www.nasdaq.com/articles/pre-market-most-active-dec-9-2013-givn-syy-infi-nok-alu-jcp-gild-aaxj-fb-bac-crnt-nj-2013", "https://www.nasdaq.com/articles/mid-afternoon-market-update-markets-trying-close-green-solarcity-falls-2013-06-04", "https://www.nasdaq.com/articles/mid-day-market-update-stocks-pare-gains-g-iii-apparel-surges-q1-results-2013-06-04", "https://www.nasdaq.com/articles/mid-day-market-update-markets-turn-mixed-colonial-properties-gains-acquisition-news-2013", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-rise-cracker-barrel-posts-upbeat-earnings-2013-06-03", "https://www.nasdaq.com/articles/pre-market-most-active-jun-3-2013-bac-qqq-clp-f-mrk-intc-bcs-nbg-siri-aapl-tsla-infi-2013", "https://www.nasdaq.com/articles/positive-data-on-infinitys-oncology-candidate-analyst-blog-2013-06-25", "https://www.nasdaq.com/articles/another-vote-confidence-infinity-2013-06-18", "https://www.nasdaq.com/articles/mid-afternoon-market-update-optimer-falls-halozyme-rockets-upwards-2013-05-16", "https://www.nasdaq.com/articles/mid-day-market-update-us-stocks-fluctuate-cisco-systems-better-expected-earnings-2013-05", "https://www.nasdaq.com/articles/insiders-buy-shares-agco-and-texas-industries-while-infinity-pharmaceuticals-sees-major", "https://www.nasdaq.com/articles/pre-market-most-active-apr-11-2013-pcs-rad-sgyp-infi-msft-acad-rlgy-qqq-ftnt-nok-bac-hpq", "https://www.nasdaq.com/articles/infinity-reports-wider-loss-analyst-blog-2013-03-08", "https://www.nasdaq.com/articles/mid-afternoon-market-update-markets-recovering-pandora-falls-anticipation-apples-streaming", "https://www.nasdaq.com/articles/infinity-pharma-at-52-week-high-analyst-blog-2013-01-02", "https://www.nasdaq.com/articles/ariad-announced-ponatinib-data-analyst-blog-2012-12-17", "https://www.nasdaq.com/articles/why-one-trader-selling-infinity-calls-2012-12-17", "https://www.nasdaq.com/articles/stocks-pointed-higher-retail-sales-fed-focus-2012-03-13", "https://www.nasdaq.com/articles/company-news-for-january-30-2012-corporate-summary-2012-01-30", "https://www.nasdaq.com/articles/amgen-celgene-and-novartis-fight-against-pancreatic-cancer-2010-10-26", "https://www.nasdaq.com/articles/infinity-provides-pipeline-update-analyst-blog-2013-01-11"], "Content": []}